Intech Investment Management LLC Buys Shares of 12,907 Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Intech Investment Management LLC bought a new stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) in the 3rd quarter, Holdings Channel.com reports. The fund bought 12,907 shares of the company’s stock, valued at approximately $56,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ally Bridge Group NY LLC bought a new position in Black Diamond Therapeutics in the second quarter valued at approximately $3,891,000. Affinity Asset Advisors LLC bought a new stake in shares of Black Diamond Therapeutics in the second quarter worth $3,029,000. TD Asset Management Inc grew its holdings in shares of Black Diamond Therapeutics by 275.9% in the 2nd quarter. TD Asset Management Inc now owns 266,312 shares of the company’s stock valued at $1,241,000 after acquiring an additional 195,464 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in Black Diamond Therapeutics during the second quarter worth about $508,000. Finally, Marshall Wace LLP acquired a new position in shares of Black Diamond Therapeutics during the 2nd quarter worth approximately $441,000. 95.47% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Wedbush restated an “outperform” rating and set a $16.00 target price on shares of Black Diamond Therapeutics in a report on Tuesday, October 8th. Piper Sandler boosted their target price on Black Diamond Therapeutics from $12.00 to $15.00 and gave the stock an “overweight” rating in a report on Monday, September 23rd. Finally, HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Black Diamond Therapeutics in a research note on Wednesday, November 6th.

Black Diamond Therapeutics Stock Up 2.6 %

BDTX stock opened at $2.41 on Monday. The company’s 50-day moving average price is $3.06 and its two-hundred day moving average price is $4.53. The firm has a market cap of $136.36 million, a P/E ratio of -1.81 and a beta of 2.47. Black Diamond Therapeutics, Inc. has a 12 month low of $2.31 and a 12 month high of $7.66.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its earnings results on Tuesday, November 5th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.09. Equities analysts predict that Black Diamond Therapeutics, Inc. will post -1.3 EPS for the current year.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.